WASHINGTON: A blood test designed to detect signals from multiple types of cancer in a single sample is moving toward a major US regulatory test, with the US Food and Drug Administration (FDA) set to convene an expert advisory panel next month to review GRAIL’s Galleri multi-cancer early detection test.
The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will meet on September 23, 2026, to discuss, make recommendations and vote on information related to GRAIL’s premarket approval application for Galleri. The meeting will be held in person and virtually.
The panel’s recommendation will not itself constitute FDA approval. FDA advisory committees provide independent scientific advice, and their recommendations are non-binding, meaning the agency makes the final regulatory decision.
What makes Galleri different from conventional cancer screening?
Galleri is designed to look for molecular signals associated with cancer in a single blood sample, rather than screening for one specific cancer at a time.
According to the FDA, the prescription-only test uses next-generation sequencing to detect cancer-specific methylation patterns in cell-free DNA isolated from whole blood. If a cancer signal is detected, the test is also designed to predict the tissue or organ where the signal may have originated.
The intended population is adults aged 50 years and older. A positive result would not, however, mean that cancer has been definitively diagnosed. The FDA specifies that a detected signal should be followed by a diagnostic workup conducted by a qualified healthcare professional.
That distinction is crucial: Galleri is intended as a screening test, not a stand-alone cancer diagnosis.
The September FDA meeting could become a major milestone
GRAIL submitted its premarket approval application to the FDA in January 2026, completing the final module of its application for Galleri. The company included data from US and UK studies in its regulatory submission.
The September meeting now gives outside experts an opportunity to examine the evidence behind the application and provide the FDA with their assessment.
The agency has specifically scheduled the committee to discuss and vote on information concerning Galleri’s premarket approval application. Public comments are also being accepted, with the FDA stating that the docket will close on September 16, one week before the meeting.
Galleri can screen for more than 50 cancer types
The technology is aimed at a fundamental limitation in current cancer screening: established screening programmes generally target individual cancers, such as breast, cervical or colorectal cancer.
Galleri is designed to search for molecular signals from more than 50 types of cancer, including cancers for which routine population screening is not currently available.
The concept is part of a rapidly developing field known as multi-cancer early detection (MCED) or multi-cancer detection testing.
These tests attempt to identify biological signals released by tumours into the bloodstream before a person develops symptoms.
But detecting a cancer signal is only the first step. A positive result can lead to further diagnostic imaging, laboratory testing or invasive procedures to establish whether cancer is actually present and, if so, where it is located.
That is one reason the FDA review is so important: the question is not simply whether a blood test can find molecular signals, but whether using such a test as a population screening tool provides enough clinical benefit to outweigh the potential harms and uncertainties.
New trial results provide both promise and uncertainty
Galleri enters the FDA review with substantial clinical evidence—but not an uncomplicated record.
The large NHS-Galleri randomized trial in England involved 142,250 adults aged 50 to 77 at enrollment and evaluated annual Galleri screening alongside standard cancer screening over three years.
The trial did not meet its primary endpoint of significantly reducing combined stage III and stage IV cancers across the specified cancer group. That finding has been a major point of discussion around the test.
At the same time, researchers reported potentially important secondary findings. By the third screening round, Galleri was associated with a 26% reduction in stage IV diagnoses among 12 prespecified cancers compared with standard screening alone. The test also increased cancer detection when added to standard screening.
Those results leave an important question for regulators: can earlier or additional cancer detection ultimately translate into meaningful improvements in patient outcomes?
Why the test is not being positioned as a replacement
Despite the appeal of detecting dozens of cancers from one blood draw, Galleri is not intended to replace established cancer screening programmes.
The test is designed to complement existing screening, including established approaches such as mammography and colonoscopy.
This matters because a multi-cancer blood test does not necessarily detect every cancer, and its ability to identify a molecular signal does not eliminate the need for conventional diagnostic testing.
A positive result can trigger a potentially lengthy diagnostic process, while a negative result cannot be interpreted as proof that a person does not have cancer.
The biggest question: does earlier detection save lives?
This is likely to be one of the central issues surrounding the broader MCED field.
Finding cancer earlier is generally considered desirable because some cancers are more treatable when diagnosed at an earlier stage. But screening technologies must demonstrate more than the ability to detect additional abnormalities.
Researchers and regulators also have to consider whether screening reduces late-stage disease, improves survival or mortality, and does so without creating excessive false-positive results, unnecessary procedures or other harms.
The NHS-Galleri trial's failure to meet its primary endpoint therefore remains significant even alongside the encouraging secondary findings.
The evidence suggests the technology has potential, but it has not yet answered every question about how population-wide multi-cancer screening would affect health outcomes.
Galleri is already available—but not FDA approved
Another important distinction is that FDA approval would not represent the first time Americans have been able to access Galleri.
The test is currently available in the US as a laboratory-developed test, meaning it can be ordered by physicians under the existing regulatory framework for such tests. However, it has not received FDA approval.
GRAIL is now seeking premarket approval, which represents a much more stringent FDA regulatory pathway for medical devices.
If approved, the regulatory status of Galleri could change substantially and potentially influence how physicians, healthcare systems and insurers view the technology.
Medicare coverage could become another major issue
Regulatory approval is only one part of the equation.
A US funding law enacted in 2024 created a pathway for Medicare coverage of FDA-approved multi-cancer early detection tests for certain adults aged 50 to 65 beginning in 2029, subject to requirements including clinical benefit.
That means the FDA's eventual decision could have implications well beyond regulatory status.
Coverage, reimbursement, clinical guidelines and physician adoption could ultimately determine whether a multi-cancer blood test becomes a widely used screening tool or remains primarily an optional test for selected patients.
Why September 23 matters
The upcoming FDA meeting will not simply decide whether a futuristic blood test sounds promising.
It will put a rapidly evolving cancer-screening technology under detailed regulatory scrutiny at a time when researchers are still debating how best to prove the clinical value of multi-cancer detection.
Galleri's ability to identify molecular cancer signals, its broad cancer coverage and encouraging findings from parts of its clinical programme make the technology significant.
But its failure to meet the primary endpoint in the large NHS trial underscores why the FDA review matters.
The September panel will examine the evidence, hear from stakeholders and vote on recommendations concerning GRAIL's application. The FDA will then make the final decision, which may or may not follow the advisory committee's recommendation.
If Galleri ultimately wins FDA approval, it could mark an important step toward bringing multi-cancer blood screening into mainstream preventive medicine.
If regulators require additional evidence or reject the application, the decision could instead reinforce the need for larger and longer studies before such tests are adopted widely.
Either way, the September review is set to provide one of the clearest regulatory tests yet for whether a single blood sample can become a practical tool for looking for cancer across the body.
Stay connected with Medical News Pakistan
CLICK HERE TO JOIN the official Medical News Pakistan WhatsApp Channel for verified global medical breakthroughs, FDA approvals, healthcare innovations, clinical research updates and the latest developments shaping medicine around the world.